<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04856878</url>
  </required_header>
  <id_info>
    <org_study_id>SD02</org_study_id>
    <nct_id>NCT04856878</nct_id>
  </id_info>
  <brief_title>Effect of Vancomycin After Catheter Replacement</brief_title>
  <acronym>VanCat</acronym>
  <official_title>Effect of Single-dose Vancomycin After Catheter Replacement for Suspected Central Line-associated Bloodstream Infection (CLABSI) on Resolution of Infection in Critically Ill Patients: A Single Center Randomized Open Label Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized controlled trial of the effect of a single-dose intravenous Vancomycin after&#xD;
      catheter replacement for suspected central line-associated bloodstream infection on&#xD;
      resolution of infection in critically ill patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients on the local intensive care unit with suspicion of central line-associated&#xD;
      bloodstream infection will be randomized to standard of care consisting of catheter&#xD;
      replacement and blood and catheter tip cultures and to standard of care plus a single-dose&#xD;
      vancomycin. The effect of the intervention on resolution of humoral inflammation and&#xD;
      negativity of blood cultures will be assessed after 48 and 96 hours.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of infection</measure>
    <time_frame>96 hours after catheter replacement</time_frame>
    <description>Composite endpoint of absolute reduction of C-reactive protein and negativity of blood culture results at 48 and 96 hours (combinated with augmented binary method)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Negativity of blood culture results</measure>
    <time_frame>48 hours and 96 hours after catheter replacement</time_frame>
    <description>Negativity of blood culture results after 48 hours, 96 hours and both</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of C-reactive protein</measure>
    <time_frame>48 hours and 96 hours after catheter replacement</time_frame>
    <description>Absolute reduction of C-reactive protein (mg/dl) in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of Procalcitonin</measure>
    <time_frame>48 hours and 96 hours after catheter replacement</time_frame>
    <description>Absolute reduction of Procalcitonin (mcg/L) in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of IL-6</measure>
    <time_frame>48 hours and 96 hours after catheter replacement</time_frame>
    <description>Absolute reduction of IL-6 (ng/L) in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of white blood cell count</measure>
    <time_frame>48 hours and 96 hours after catheter replacement</time_frame>
    <description>Absolute reduction of white blood cell count (G/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day survival</measure>
    <time_frame>28 days</time_frame>
    <description>Survival after a follow-up of 28 days or until hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU-free days at day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Cumulative days not admitted to the intensive care unit in patients alive at day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressor-free days at day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Cumulative days of no vasopressor therapy in patients alive at day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invasive mechanical ventilation-free days at day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Cumulative days of no invasive mechanical ventilation in patients alive at day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibiotic-free days at day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Cumulative days of no antibiotic therapy in patients alive at day 28</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of central line-associated bloodstream infections</measure>
    <time_frame>from blood cultures drawn before replacement and at 48 and 96 hours</time_frame>
    <description>Definition according to the National Healthcare Safety Network (NHSN - CDC) Patient Safety Component Manual 2021</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood culture</measure>
    <time_frame>from blood cultures drawn before replacement and at 48 and 96 hours</time_frame>
    <description>positivity of blood cultures</description>
  </other_outcome>
  <other_outcome>
    <measure>Vancomycin level in plasma</measure>
    <time_frame>24 hours after administration</time_frame>
    <description>Vancomycin level (mg/L) in plasma after 24 hours</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of acute kidney injury</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of new or worsening acute kidney injury according to the definition and classification of the KDIGO 2012 guidelines</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypersensitivity reaction to Vancomycin</measure>
    <time_frame>6 hours after catheter replacement</time_frame>
    <description>Hypersensitivity reaction in the following 6 hours after vancomycin administration/catether replacement. Hypersensitivity reaction is defined as any new of the following symptoms: flushing, erythema, pruritus, pains or muscle spasms in the back or chest, dyspnea or hypotension.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Central Line-associated Bloodstream Infection (CLABSI)</condition>
  <condition>Catheter-related Bloodstream Infection</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care (SOC) + single-dose intravenous vancomycin 15mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care (SOC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>The investigational drug vancomycin is administered intravenously through a newly inserted peripheral or central venous catheter directly after removal of the 'old' catheters. The investigational drug is administered with a volume of 500ml normal saline (NaCl 0.9%) with a rate of maximal 1g per hour.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Suspected central line-associated bloodstram infection defined as:&#xD;
&#xD;
          -  Catheterization with a non-tunneled CVC and&#xD;
&#xD;
          -  Clinical signs of local catheter infection or any increase in humoral inflammatory&#xD;
             markers (PCT, CRP, WBC) or elevated body temperature ≥ 38.3°C not otherwise explained.&#xD;
&#xD;
        Baseline CRP at screening ≥ 100 mg/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known positive blood cultures at the time of randomization&#xD;
&#xD;
          -  High risk situation warranting immediate empiric antibiotic therapy:&#xD;
&#xD;
          -  endovascular implant (prosthetic valve, pacemaker, vascular graft)&#xD;
&#xD;
          -  high-risk for endocarditis warranting endocarditis-prophylaxis&#xD;
&#xD;
          -  Septic shock&#xD;
&#xD;
          -  Catheter replacement not feasible or no further indication for central venous&#xD;
             catheterization&#xD;
&#xD;
          -  Known hypersensitivity to vancomycin or any component of the formulation.&#xD;
&#xD;
          -  Administration of Vancomycin, Teicoplanin, Daptomycin or Linezolid &lt;48 hours before&#xD;
             enrolment.&#xD;
&#xD;
          -  Enrolment in another clinical study&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 16, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Central Line-associated Bloodstream Infection</keyword>
  <keyword>Catheter-related Bloodstream Infection</keyword>
  <keyword>Vancomycin</keyword>
  <keyword>Critical Care</keyword>
  <keyword>Bloodstream Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

